Prescribing and costs of topical antifungals for onychomycosis by podiatrists in Medicare Part D

Haidee Oren and Karin D Richmond

SAP Podiatry, 2026

Abstract: Introduction: Onychomycosis is common in older adults and in diabetes, and podiatrists are frequent first-line providers of nail care, yet little is known about their topical antifungal prescribing in Medicare Part D. Methods: We used the Centers for Medicare and Medicaid Services Part D Prescribers by Provider and Drug public use files for 2014 through 2024, selecting records with podiatry as the prescriber specialty and efinaconazole, tavaborole or ciclopirox as the generic drug. Annual claims, 30-day fills and spending were estimated, log-linear time trends were fitted, and state-level per-beneficiary costs were described for 2024. Results: Annual claims increased from 134,117 to 348,043 and drug costs from 7.7 to 58.1 million USD. Thirty-day fills grew by 9.3% per year (95% CI 7.1-11.5). The share of branded agents rose from 0.1% to 14.3% (

Date: 2026
References: Add references at CitEc
Citations:

Downloads: (external link)
https://southam.pub/journals/files/pod/pod2026259en.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cwf:podart:pod2026259

DOI: 10.62486/pod2026259

Access Statistics for this article

More articles in SAP Podiatry from South American Publishing
Bibliographic data for series maintained by South American Publishing Journals Manager ().